Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 195-202

  Meyer, G C ^a   Moebius, U ^a,c   Rudy, W ^a,b   Batrla, R ^a   Meuer, S C ^b   Wallwiener, D ^b   Guckel B ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Onkologisches Labor 221 ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031782839     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_31     Document Type: Article

References (21)

1. T Boon, P van der Bruggen, 1996: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
2. DL Mueller, MK Jenkins, RH Schwartz, 1989: Clonal expansion versus functional clonal inactivation; a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 455-480.
3. RH Schwartz, 1990: A culture model for T lymphocyte clonal anergy. Sience. 248, 1349-1356.
4. L Chen, S Ashe, WA Brady, I Hellström, KE Hellström, JA Letbetter, P McGowan, PS Linsley, 1992: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 71, 1093-1102.
5. + T cells by B7-transfected melanoma cells. Sience. 259, 368-370.
6. B Gückel, M Lindauer, W Rudy, A Habicht, M Siebels, S Kaul, G Bastert, SC Meuer, U Moebius, 1995: CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes. Cytokines Mol. Ther. 1, 211-221.
7. B Gückel, U Moebius, SC Meuer, S Kaul, G Bastert, D Wallwiener, 1996: Development of immunogenic breast and ovarian tumor cells for vaccination: improved immunogenicity and induction of cytolytic T lymphocytes after CD80-transfection. GebFra. 56, 574-584
8. T Boon, P Coulie, M Marchand, P Weynants, T Wölfel, V Brichard, 1994: Genes coding for tumor rejection antigens: perspectives for specific immuntherapy. In: De Vita VT, S. Hellmann, S. Rosenberg (eds) Important advances in oncology, J. B. Lippincott Company, Philadelphia. pp53-69.
9. ML Disis, E Calenoff, G McLaughlin, AE Murphy, W Chen, B Groner, M Jeschke, N Lydon, E McGlynn, RB Livingston, R Moe, MA Cheever. 1994a: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20.
10. ML Disis, JW Smith, AE Murphy , W Chen, MA Cheever. 1994b: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54, 1071-1076.
11. B Fisk, LB Tracy, JT Wharton, CG loannides, 1994: Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor specific T lymphocyte lines. J. Exp. Med. 181, 2109-2117
12. CG loannides, B Fisk, KR Jerome, T Irimura, JT Wharton, OJ Finn. 1993: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151, 3693-3703.
13. EJ Stevens, L Jacknin, PF Robbins, Y Kawakami, EL Gamil, A Rosenberg, R Yannelli. 1995: Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J. Immunol. 154, 762-771.
14. C Scheibenbogen, K-H Lee, S Mayer, A Jochim, U Moebius, W Herr, H-G Rammensee, U Keilholz. 1997: A sensitive ELISPOT assay for detection of HLA class I restricted CD8+ T lymphocytes specific for influenca pepetide epitope in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3, 221-226
15. M Salcedo, F Momburg, GJ Hämmerling, HG Ljunggren. 1994: Resistance to natural killer cell lysis conferred by TAPI/2 genes in human antigen-processing mutant cells. J. Immunol. 153(4), 1702-1708.
16. A Habicht, M Lindauer, P Galmbacher, W Rudy, J Gebert, H-K Schackert, SC Meuer, U Moebius. 1995: Developement of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7) is not sufficient to restore impaired primary T cell activation in vitro. Eur. J. Cancer 31 A, 2396-2402.
17. W Rudy, B Gückel, M Siebels, M Lindauer, SC Meuer, U Moebius. 1997: Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-γ. J. Int. Immunol. 9, 853-860.
18. M Lindauer, H-K Schackert, J Gebert, W Rudy, A Habicht, M Siebels, SC Meuer, U Moebius. 1996: Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells. J. Mol. Med. 74, 43-49.
19. M Lindauer, W Rudy, A Habicht, M Siebels, B Gückel, M v. Knebel Doeberitz, SC Meuer, U Moebius. 1997: Requirement of CD54, CD80, and class II MHC expression of a human colorectal cancer cell line to induce primary T cell activation and class I MHC restricted cytolytic T lymphocytes. Submitted.
20. GC Meyer, B Gückel, R Batrla, SC Meuer, D Wallwiener, U Moebius. 1997: The potential of CD80 transfected human mamma carcinoma cells to induce peptide specific T lymphocytes in an allogeneic HLA-A2.1+ matched situation. Submitted.
21. B Gückel, GC Meyer, W Rudy, R Batrla, SC Meuer, G Bastert, D Wallwiener, U Moebius. 1997: Interleukin 12 requires initial CD80 mediated T cell activation to support immune responses towards human breast and ovarian carcinoma. Submitted.